Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
I am on my second container and will continue to purchase
Component-Level Trial Findings CJC-1295 (without DAC, modified GRF 1-29) Phase 1 and Phase 2 work described: Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683) IGF-1 elevation of 1.5-3x baseline at 1-2 weeks Mild facial flushing post-injection in some participants No serious adverse events at studied doses CJC-1295 with DAC The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683)
With the results of these tests, nutrient therapy can be tailored to the patient's specific needs and symptoms, improving methylation and reducing symptoms associated with histamine intolerance
El Hadri K, Smith R, Duplus E, El Amri C
Garo Kassabian for his unique ability to combine aesthetic expertise with advanced metabolic medicine
The Nutraceutical industry needs no introduction
US$ 22.41
US$ 29.18
US$ 28.90
US$ 20.60
US$ 27.60
US$ 20.05
US$ 24.10
